Sprim Als: Australia's Prota Therapeutics secures $21M in financing led by SPRIM Global Investments

Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, has on Tuesday announced financing of $21 million in equity and debt financing. The round is led by Singapore-based SPRIM Global Investments (SGI).